Based on the targeting capability to prostate cancer cells through receptor-mediated endocytosis, P-SNPs@DOX released more DOX inside PSMA-positive prostate cancer cells, thereby increasing the anticancer efficacy. This evidence concerns the gene FOLH1 and prostate carcinoma.